TP53 and neoplasm: Finally, dysregulation of the p53-MDM2 pathway contributes as MDM2 overexpression leads to the degradation of p53, inhibiting tumor suppression and increasing MYCN activity, thus contributing to poor prognosis and resistance to therapy (51, 52).